Phase 2 N=44 Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia
Leukemia, Myelomonocytic, Chronic
Primary: Objective Response Rate (ORR) — 0; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=53 Ketogenic Diet (KD) in Alcoholism
Alcoholism
Primary: Withdrawal Symptoms Measured Using the Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar) — 4.16; 6.57 score on a scale — p=0.067
Phase 1 N=8 A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4041 in Healthy Volunteers
Smoking Cessation
Primary: Number of Adverse Events — 5; 0; 1; 1 Participants
Phase 3 N=79,560 Telemedicine Control Tower for the Operating Room: Navigating Information, Care and Safety
Surgery · Surgery--Complications · Perioperative/Postoperative Complications
Primary: Thirty-day Postoperative Mortality — 899; 866 Participants — p=0.41
Phase 4 N=50 Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation
Renal Transplant Rejection · Kidney Transplant Failure and Rejection
Primary: Mean C/D Ratio — 1.68; 1.47; 1.86; 1.85 ng/mL*1/mg
Phase 3 N=55 Effect of Evolocumab on Coronary Atherosclerosis
Cardiovascular Disease · Hyperlipidemia
Primary: Change in Noncalcified Coronary Artery Plaque Volume (NCPV) — -45 mm^3
N/A N=833 ABLATOR Brazil - Ablation Observational Study (Registry)
Atrial Fibrillation
Primary: Unsuccessful Treatment Rate — 22; 21 Participants
N/A N=44 Cirrhosis Medical Home
Cirrhosis, Liver
Primary: Enrollment Rate — 20; 20 Participants
N/A N=112 ReSET Aim 1b: Restarting Safe Education and Testing for Children With Medical Complexity - COVID-19 Testing in School With Children and Staff
Children With Medical Complexity (CMC) · COVID-19
Primary: Change in Protocol Uptake: Number of Children and Staff Consented Compared to Number of Approached — 71; 17 Participants
Phase 4 N=20 Buffered Local Anesthetic
Dental Pain
Primary: Pain Score as Measured by the Behavior Pain Scale — 2.24; 2.61 score on a scale — p=0.005
Phase 2 N=5 LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Melanoma
Primary: Dose Limiting Toxicity (DLT) [Phase I] — 1 Participants
N/A N=24 Causal Role of Frontostriatal Circuitry in Goal-directed Behavior
Executive Function
Primary: Percentage of the Trials That the Participant Chooses to Perform the Hard Task — 33.2; 32.9; 33.6; 37.1 Percentage of trials
N/A N=120 Study to Evaluate the OrthoCor Active System for Pain Relief
Pain
Primary: Primary Safety EndPoint — 2; 2 Participants
Phase 2 N=40 S-Equol in Alzheimer's Disease 2 Trial
Alzheimer Disease
Primary: Cytochrome Oxidase/Citrate Synthase (COX/CS) Activity — -0.0000049; 0.0000195; 0.0000245 1/(seconds multiplied by micromoles) — p=>0.05
Phase 2 N=25 A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial
NASH - Nonalcoholic Steatohepatitis
Primary: Safety and Tolerability of LPCN 1144 — 10 Participants